Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

Inclusion Criteria: * male and females 40 to 80 years of age (inclusive) * COPD diagnosis * Current or previous smokers with a cigarette smoking history of at least 10 pack- * Post-albuterol FEV1/FVC of 0.70 or less * Post-albuterol FEV1 of 35% to 80% (inclusive) Exclusion Criteria: * Pregnant or lactating females * current diagnosis of asthma * respiratory disorders other than COPD * clinically significant cardiovascular, neurological, psychiatric, renal, immunological, endocrine, or hematological abnormalities that are uncontrolled * clinically significant sleep apnea * previous lung resection surgery * clinically significant abnormalities confirmed by chest x-ray that are not related to COPD * hospitalization for COPD within 3 months of screening * use of antibiotics for lower respiratory tract infection within 6 months of screening * abnormal and clinically significant 12-lead ECG findings * current malignancy in remission for less that 5 years * medical conditions that would contraindicate the use of anticholinergics * positive hepatitis B or C test * history of alcohol or drug abuse * unable to withhold albuterol for 6 or more hours * use of long term oxygen therapy * conditions that would limit the validity of informed consent * use of GW642444 or GSK233705 in previous studies * use of an investigation drug with 30 days of screening * use of inhaled corticosteroids (ICS) at a dose greater than 1000mcg of fluticasone propionate or equivalent * hypersensitivity to beta-agonists * concurrent use of long-acting beta-agonists (LABA) or long-acting muscaring antagonists, LABA/ICS combination products, cytochrome p450 inhibitors, oral or depot corticosteroids, theophyllines, oral beta agonists, oral leukotrine modulators, inhaled short acting anticholinergics.